Tenax Therapeutics
TENX
111 hedge funds and large institutions have $441M invested in Tenax Therapeutics in 2026 Q2 according to their latest regulatory filings, with 45 funds opening new positions, 40 increasing their positions, 13 reducing their positions, and 14 closing their positions.
513% more call options, than puts
Call options by funds: $33.3M | Put options by funds: $5.43M
221% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 14
208% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 13
118% more capital inflows, than outflows
Capital inflows: $237M | Capital outflows: $109M
37% more funds holding
Funds holding: 81 → 111 (+30)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
386.35% less ownership
Funds ownership: 467.42% → 81.07% (-386%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$46.2M |
| 2 |
VC
Vivo Capital
Palo Alto,
California
|
+$29.3M |
| 3 |
BlackRock
New York
|
+$21.9M |
| 4 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
+$11.3M |
| 5 |
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$9.58M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$29.9M |
| 2 |
VA
VR Adviser
New York
|
-$26.8M |
| 3 |
Armistice Capital
New York
|
-$7.66M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$5.23M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$4.47M |
TENX Hedge Fund Activity: Q2 2026 in Review
111 of the 8,354 institutional investors tracked by Wall St. Rank reported a position in Tenax Therapeutics (TENX) for Q2 2026, worth a combined $441M — up 29% from $341M a quarter earlier.
Buyers outnumbered sellers: 45 funds opened new TENX positions and 14 closed out — a net gain of 31 holders — while 40 added to existing stakes and 13 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $46.2M. The largest seller was T. Rowe Price Associates, cutting an estimated $29.9M.
- 111 institutional investors held Tenax Therapeutics (TENX) as of Q2 2026, up from 81 in Q1 2026.
- Funds reported $441M of Tenax Therapeutics stock for Q2 2026, up 29% quarter-over-quarter.
- 45 funds opened new Tenax Therapeutics positions in Q2 2026 and 14 closed out, a net change of +31 holders.
- The largest Tenax Therapeutics buyer in Q2 2026 was Fidelity Investments, an estimated $46.2M added.
- The largest Tenax Therapeutics seller in Q2 2026 was T. Rowe Price Associates, an estimated $29.9M sold.
Based on aggregated 13F filings for Q2 2026.